iifl-logo-icon 1

Dishman Pharmaceuticals and Chemicals Ltd Merged Share Price

301.2
(2.71%)
May 29, 2017|03:57:47 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Dishman Pharmaceuticals and Chemicals Ltd Merged KEY RATIOS

Sector

Pharmaceuticals

Open

288.2

Prev. Close

293.25

Turnover(Lac.)

4,866.19

Day's High

304.2

Day's Low

278

52 Week's High

0

52 Week's Low

0

Book Value

0

Face Value

2

Mkt Cap (₹ Cr.)

4,861.2

P/E

200.7

EPS

1.5

Divi. Yield

0.33

Dishman Pharmaceuticals and Chemicals Ltd Merged Corporate Action

No Record Found

Dishman Pharmaceuticals and Chemicals Ltd(Merged) NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Dishman Pharmaceuticals and Chemicals Ltd(Merged) SHAREHOLDING SNAPSHOT

24 Aug, 2024|09:40 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 61.40%

Foreign: 0.00%

Indian: 61.40%

Non-Promoter- 20.84%

Institutions: 20.84%

Non-Institutions: 17.75%

Custodian: 0.00%

Share Price

Dishman Pharmaceuticals and Chemicals Ltd Merged FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2016Mar-2015Mar-2014Mar-2013

Equity Capital

16.14

16.14

16.14

16.14

Preference Capital

0

0

0

0

Reserves

895.36

820.29

780.94

709.28

Net Worth

911.5

836.43

797.08

725.42

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2016Mar-2015Mar-2014Mar-2013

Revenue

510.39

492.24

473.28

484.63

yoy growth (%)

3.68

4

-2.34

4.58

Raw materials

-193.84

-213.87

-175.64

-179.19

As % of sales

37.97

43.44

37.11

36.97

Employee costs

-65.89

-58.88

-58.37

-58.21

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2016Mar-2015Mar-2014Mar-2013

Profit before tax

120.25

103.82

118.83

94.7

Depreciation

-44.25

-44.13

-44.13

-35.34

Tax paid

-33.1

-45.34

-32.04

-31.52

Working capital

85.06

133.26

-3.47

130.15

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2016Mar-2015Mar-2014Mar-2013

Growth matrix (%)

Revenue growth

3.68

4

-2.34

4.58

Op profit growth

15.25

-15.91

4.15

16.71

EBIT growth

9.86

-8.56

27.54

17.88

Net profit growth

49.02

-32.61

37.37

40.9

View Ratios
Particulars (Rupees in Crores.)Mar-2017Mar-2016Mar-2015Mar-2014Mar-2013

Gross Sales

1,633.86

1,561.85

1,560.35

1,373.23

1,267.56

Excise Duty

0

0

0

0

0

Net Sales

1,633.86

1,561.85

1,560.35

1,373.23

1,267.56

Other Operating Income

79.83

34.2

28.39

12.07

4.65

Other Income

26.13

26.54

86.91

24.87

17.78

Dishman Pharmaceuticals and Chemicals Ltd Merged Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,775.75

150.914,20,027.58237.820.774,409.7498.75

Divis Laboratories Ltd

DIVISLAB

4,855.95

78.491,30,370.294300.612,063507.93

Cipla Ltd

CIPLA

1,574.55

32.241,28,058.811,055.940.823,752.25346.4

Zydus Lifesciences Ltd

ZYDUSLIFE

1,178.7

27.871,21,729.161,700.80.254,035.4156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,954.5

28.241,16,346.951,417.20.575,823.91,458.7

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Dishman Pharmaceuticals and Chemicals Ltd Merged

Management

Register Office

Registrar Office

Managing Director

JANMEJAY RAJNIKANT VYAS

Whole-time Director

DEOHOOTI JANMEJAY VYAS

Director

ASHOK CHANDRAKANT GANDHI

Director

RAJENDRA SHANTILAL SHAH

Director

SANJAY SHAILESHBHAI MAJMUDAR

Managing Director & CFO

ARPIT JANMEJAY VYAS

Director

SUBIR KUMAR DAS

Director

MARK CHRISTOPHER GRIFFITHS

Company Secretary

SHRIMA GAURANGBHAI DAVE

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Reports by Dishman Pharmaceuticals and Chemicals Ltd Merged

Summary

Dishman Pharmaceuticals and Chemicals Ltd is a recognized supplier of cost-effective, high quality chemical services and products to the global pharmaceutical and chemical industry. They are involved in the manufacture of active pharmaceutical ingredients (API), API intermediates, quaternary ammonium compounds and fine chemicals. They are having their manufacturing facility at Ahmedabad in Gujarat. Dishman Pharmaceuticals and Chemicals Ltd was incorporated in the year 1983 as a research-oriented organization. The company set up their first manufacturing unit in Naroda for phase Transfer Catalysts. The company earned the status of Quat Company by establishing themselves in the quat business.In the year 1995, the company formed a joint venture company with Schtz & Co, Germany called as Schutz Dishman Biotech Private Ltd. They manufacture Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution, for the European market. In the year 1997, the company commenced their production in the unit I at Bavla.In the year 1998, the company established marketing subsidiaries Dishman Europe in London and Dishman USA in Middlesex New Jersey. In the year 2001, they signed the first contract manufacturing project. The company converted their entire Bavla facility into 100% Export oriented Unit in the year 2003. Also, they acquired Chemconserve BV in Netherland.In April 2004, the company incorporated a wholly owned subsidiary company namely Dishman Interna
Read More

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp